鸟苷酸环化酶激活剂维利西呱在心力衰竭治疗中的研究进展

Research progress of guanylate cyclase activator vericiguat in the treatment of heart failure

随着对心力衰竭(心衰)发病机制及治疗方法的研究不断深入,近年来许多新型药物取代以往“强心、利尿、扩血管”的心衰传统治疗理念,采用神经内分泌调控为理论基础的治疗药物。维利西呱是一种新型的可溶性鸟苷酸环化酶激活剂,它也可以通过一氧化氮(NO)-可溶性鸟苷酸环化酶(sGC)-环磷鸟嘌呤核苷(cGMP)通路,最终产生增加心肌细胞内cGMP浓度的效应,从而发挥治疗慢性心衰的功效,同时维利西呱对于心衰合并症例如慢性肾功能不全(CKD)的治疗也有所帮助。目前维利西呱正逐渐成为治疗心衰的热点药物。本文对于维利西呱的相关研究进展及其作用机制和临床应用展望进行综述。

With the deepening of research on the pathogenesis and treatment of heart failure,in recent years,many new drugs have replaced the traditional treatment concept of heart failure of "cardiotonic,diuretic,vasodilator",and have adopted neuroendocrine regulation as the theoretical basis of the therapeutic drugs.Vericiguat is a novel soluble guanylate cyclase activator.It can also increase the concentration of cGMP in cardiomyocytes through the nitric oxide(NO)-soluble guanylate cyclase(sGC)-cyclic guanosine monophosphate(cGMP) pathway,thereby playing a role in the treatment of chronic heart failure.Vericiguat is also helpful in the treatment of heart failure complications such as chronic kidney disease(CKD).At present,vericiguat is gradually becoming a popular drug in the treatment of heart failure.This paper reviews the research progress,mechanism of action and prospect of clinical application of vericiguat.